Navigation Links
Alpha in Medical Technology

RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days

... (TM) (silodosin), a new, uniquely selective alpha blocker for the treatment of the signs and ... prostate and bladder neck, which is mediated by alpha 1A adrenoreceptors," said Leonard S. Marks, MD, ... semen), an expected treatment effect of selective alpha blockers, which occurred in 28 percent of men ...

Generic Substitutes Less Effective/Safe Than Branded Medications in Treating Lower Urinary Tract Symptoms

... (AUA) showing that generic substitutes for alpha blockers and 5-alpha reductase inhibitors ... weeks, the study tested 212 men taking branded alpha blockers or 5-ARIs with an average age of 64, who ... dysfunction (3.6 percent) for those switching alpha blockers, and ejaculatory dysfunction (4.7 ...

Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting

... disease previously untreated with interferon alpha and who are at least 18 years of age. The ... DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS alpha interferons, including PEGINTRON, may cause or ... and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune ...

Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients

... disease previously untreated with interferon alpha and who are at least 18 years of age. The ... DISORDERS AND RIBAVIRIN-ASSOCIATED EFFECTS alpha interferons, including PEGINTRON, may cause or ... and toxic epidermal necrolysis to interferon alpha or any other component of the product, autoimmune ...

Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)

... the company's new, uniquely selective alpha blocker for the treatment of the signs and ... antagonist that binds with high affinity to the alpha 1a receptors concentrated in the prostate, ... in BPH symptoms. The binding affinity for the alpha 1B receptors that regulate smooth muscle ...

FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C

... who failed previous treatment with combination alpha interferon/ribavirin were retreated with ... previously treated with nonpegylated or pegylated alpha interferon and ribavirin combination therapy, ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON, may cause or ...

ESBATech's Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity

... Phase I/IIa clinical development of its anti-TNF alpha antibody fragment ESBA105 in osteoarthritis (OA). ... by episodes of local inflammation and thus, TNF alpha represents a highly promising target. TNF alpha is excessively generated in OA by chondrocytes, ...

Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C

... have not been previously treated with interferon alpha and who are at least 18 years of age. ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... of the hair) is also often associated with alpha interferons including PEGINTRON. ...

Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Top-Line Results of Boceprevir Phase II Study Showed High Rate of Sustained Response (SVR) in Genotype 1 Treatment-Naive Hepatitis C Patients

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder

... whether or not silodosin -- an investigational alpha blocker -- would prolong the QT interval on an ... Silodosin is a novel, highly uroselective alpha (1A)-adrenoceptor antagonist originally developed ... markets. Silodosin preferentially binds to the alpha (1A) receptors in the prostate and bladder neck ...

Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting

... failed prior treatment with interferon alpha (pegylated or non-pegylated) and ribavirin ... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ...

Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia

... Silodosin is highly uroselective for the alpha (1A) receptors located in the prostate and ... The selective binding of silodosin to the alpha (1A) receptors is substantially greater than the binding to the cardiovascular-associated alpha (1B) receptors and thereby maximizes target organ ...

Schering-Plough Reports Top-Line Results of the IDEAL Study

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting

... have not been previously treated with interferon alpha and who are at least 18 years of age. Important ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

Initial Results of Phase II Study with HCV Protease Inhibitor Boceprevir in Treatment-Naive Hepatitis C Patients Show a High Rate of Early Virologic Response

... have not been previously treated with interferon alpha and who are at least 18 years of age. PEGINTRON ... U.S. Labeling for PEGINTRON and REBETOL alpha interferons, including PEGINTRON and INTRON(R) A, ... been observed in patients treated with interferon alpha therapies, including PEGINTRON and INTRON A. ...

EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimer's, Schizophrenia and Huntington's Diseases

... is developing EVP6124, a selective, orally active alpha 7 Nicotinic Acetylcholine Receptor Agonist for ... to begin in early 2008. It is anticipated that alpha 7 agonist compounds will improve cognitive ... Senior Director and program executive for the alpha 7 initiative. Dr. Gawryl has more than 20 years ...

European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy

... and ribavirin combination therapy or interferon alpha monotherapy did not result in a sustained ... who failed previous treatment with combination alpha interferon/ribavirin therapy were retreated ... to one or more courses of interferon alpha plus ribavirin combination therapy (HCV-RNA ...

Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years

... treatment with AVODART (dutasteride) and the alpha blocker tamsulosin provides significantly greater ... belongs to a class of medicines known as 5 alpha reductase inhibitors (5 ARIs), which shrink the prostate over time. Tamsulosin is an alpha blocker, a class of medicines that relaxes ...

Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen

... and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C

... and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS (R) (Peginterferon alfa-2a), may cause ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer

... targeted cancer therapeutics that harness the unique characteristics of alpha particle emitters and are potent, well-tolerated and convenient to use. ... antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, ...

Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings

... hormone products currently on the market, which are both ER beta and ER alpha agonists that have been shown to increase the risk for breast and uterine ... the increased risk of breast and uterine cancers is associated with ER alpha activation and that ER beta blocks the growth promoting effects on breast ...

New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients

... disease and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients

... that CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) - provides sustained improvement in symptoms ... The data suggest that based on standard regimens for each of the TNF alpha blockers for CD, CIMZIA may be less costly than the two biologics ...

Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin

... II results. Alpharadin is a novel bone-seeking therapeutic based on the alpha particle emitter radium-223 and may target skeletal metastases from ... antibodies and other tumor-targeting molecules by linking them to the alpha particle emitter thorium-227. The Company is headquartered in Oslo, ...

New Research Provides Evidence that Tea May Improve Attention and Focus, Keep Brain Cells Healthy, & Influence Genetics in Cancer

... barrier where it affects the brain's neurotransmitters, and increases alpha brain-wave activity. This alpha brain rhythm is known to induce a calmer, yet more alert, state of mind. A ...

Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival

... . Important Safety Information alpha interferons, including PEGINTRON(TM), may cause or aggravate fatal or ... events have been observed in patients treated with interferon alpha therapies, including PEGINTRON(TM). Full prescribing information in the ...

Human Genome Sciences Reports Progress With Late-Stage Products and New Initiatives

... PRODUCTS: ON TRACK TO COMMERCIALIZATION Albuferon(R) (albumin-interferon alpha 2b), a novel long-acting form of interferon alpha for the treatment of chronic hepatitis C At the 900-mcg dose now being ...

PEGASYS(R)/COPEGUS(R) Show Benefit in Hard-to-Treat Latino Population with Hepatitis C

... disease and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

Roche Gains Access to Important Oncology Target With Potential for Treating Major Cancers Such as Breast and Lung; First Drug Candidate in Phase I Clinical Testing

... of agents that inhibit the pathway at the level of PI3-K, particularly the alpha isoform. Such agents are expected to inhibit proliferation and overcome ... when it secured a collaboration with Genentech in relation to its PI3-K alpha program. The company also has proprietary, unpartnered program targeting ...

Human Genome Sciences Modifies Dosing in Achieve Trials of Albuferon(R)

... About Albuferon Albuferon is a novel, longer-acting form of interferon alpha that was created using the proprietary HGS albumin-fusion technology. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a broad ...

Roche responds to announcement of 'IDEAL' hepatitis C trial results

... disease and histological evidence of cirrhosis (Child-Pugh class A). alpha interferons, including PEGASYS (Peginterferon alfa-2a), may cause or ... may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical ...

MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders

... Serono is a leader in fertility treatments, with Gonal-f (R) (follitropin alpha for injection), Luveris (R) (lutropin alfa for injection) and Ovidrel (R) Prefilled Syringe (choriogonadotropin alpha injection). The company has strong market positions in neurodegenerative ...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

... most comprehensive Phase 3 development program to date for an anti-TNF- alpha biologic therapy. With ongoing studies for the treatment of rheumatoid ... most comprehensive Phase 3 development program to date for an anti-TNF- alpha biologic therapy. With ongoing studies for the treatment of rheumatoid ...
Other Contents
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/8/2015)... 2015  Infinisource, a leading provider of SaaS-based Human ... a leading supplier of biometric identification and security ... most advanced biometrically-enabled time clock, the companies announced ... is setting a bold, new standard for the ... small and mid-size employer. When connected to the ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... for its touch fingerprint sensor FPC1025 from the distributor ... Deliveries will commence during Q2 2015 although the major ... 2015. The sensors will be used by smartphone manufacturers ... of 110 MSEK is included in the communicated revenue ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
(Date:5/4/2015)... For partners who’d like to become ... Astroglide TTC™ (Trying to Conceive) . Unlike traditional ... levels, Astroglide TTC™ is specially formulated to provide a ... Centers for Disease Control, an average of one ... sustaining a pregnancy, and over 7.4 million women ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 ... just released the first-ever congenital heart disease ... Catheterization Laboratory (PCCL) accreditation. Driven by the ... are a comprehensive review of interventional procedures ... heart disease. , “The ACE CHD Standards ...
(Date:5/4/2015)... California (PRWEB) May 04, 2015 Sara ... a physician practice management firm in Los Angeles associated ... today the patent-pending status of The Sara Soulati Health ... Soulati in 2010, is a lifestyle modification and disease ... April 2015 to the U. S. Patents and Trademarks ...
(Date:5/3/2015)... ANGELES, American Telemedicine Association 2015 Meeting & Tradeshow ... e-health solutions, a full-service telemedicine and mobile health ... new platform, VITA health services for chronic disease ... services platform enables remote patient monitoring of a ... heart failure (CHF), diabetes, COPD, hypertension and other ...
(Date:5/3/2015)... (PRWEB) May 03, 2015 “ BolehVPN ” ... Report, which features the latest and coolest technology products available ... for NewsWatch, conducted the review and shared with viewers how ... everyone does these days is on computers and even more ... families and meet people all over the world. In terms ...
Breaking Medicine News(10 mins):Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 2Health News:Astroglide Announces the Birth of Its New Baby: Astroglide TTC 3Health News:Accreditation for Cardiovascular Excellence (ACE) Publishes New Standards for Pediatric and Adult Congenital Cardiac Catheterization Laboratories 2Health News:CEO Sara Soulati Announces Patent-Pending Designation For The Sara Soulati Health For Life Program 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:A Method to Keep Private Information Secure was Featured on NewsWatch Television 2
Other TagsOther Tags